Nov 29, 2012 12:00am EST Pieris Presents Data and Reveals Targets for Anticalin® Bispecific PRS-190 at European Antibody Congress
Oct 09, 2012 12:00am EDT Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
Apr 04, 2012 12:00am EDT Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the AACR Annual Meeting
Feb 07, 2012 12:00am EST Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin® Program
Dec 13, 2011 12:00am EST Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual Meeting
Nov 15, 2011 12:00am EST Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
Oct 19, 2011 12:00am EDT EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
Oct 19, 2011 12:00am EDT Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin® Pipeline Development
May 23, 2011 12:00am EDT Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin® PRS-080 Hepcidin Antagonist Drug Program
